News Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Delayed Nasdaq Stockholm Other stock markets 06:42:02 2024-04-26 am EDT			5-day change	1st Jan Change
40.65 ^SEK	+0.99%		+2.28%	+0.88%

Feb. 14	Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
Feb. 12	US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market	Apr. 22	AQ
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants	Apr. 19	AQ
Important information to holders of warrants series TO6: subscription period begins today	Apr. 18	AQ
Notice of annual general meeting of Xspray Pharma AB (publ)	Apr. 18	AQ
Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants	Apr. 10	AQ
Xspray Pharma publishes its Annual Report 2023	Mar. 27	AQ
Xspray Pharma Q4 2023 - NDA-resubmission accepted by the FDA	Feb. 16	AQ
Interim Report Fourth Quarter 2023	Feb. 14	AQ
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 14	CI
FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc, PDUFA Date set to 31 July	Feb. 13	AQ
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024	Feb. 12	BU
US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment	Feb. 12	MT
FDA Accepts Xpray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July	Feb. 12	AQ
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA	Feb. 12	CI
Xspray Pharma appoints Michael af Winklerfelt as acting CFO	Feb. 07	AQ
Xspray Pharma AB Appoints Kerstin Hasselgren as Head of IR	Feb. 07	CI
Xspray Pharma AB Announces CFO Changes	Feb. 07	CI
New number of shares and votes in Xspray Pharma	Dec. 29	AQ
Xspray Pharma raises SEK 92.3 million through warrants TO5	Dec. 01	AQ
Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage	Nov. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Summary

Filters